Skip to main content
. 2021 Apr;62(4):199–203. doi: 10.11622/smedj.2020026

Fig. 1.

Fig. 1

Chart shows breakdown of funding for Singaporean pulmonary arterial hypertension patients on PDE5 inhibitors. MAF: Medication Assistance Fund; MSW: medical social worker; PDE5: phosphodiesterase type 5; SHF: Singapore Heart Foundation